Investor FAQs

Investor FAQs

Show All
When was the Company founded/incorporated?

We were originally incorporated in the state of Minnesota in December 2002 and reincorporated in the state of Delaware in July 2004. In 2017, we changed our name from EnteroMedics Inc. to ReShape Lifesciences Inc.

Where are the Company offices located?

Our principal executive offices are located at 1001 Calle Amanecer, San Clemente, CA 92673, and our telephone number is (949) 429-6680.

When did the Company go public?
  • The Company completed its initial public offering for the OTC markets on November 15, 2007
  • The Company listed on The Nasdaq Capital Market on June 16, 2021
What exchange does the Company trade and what is the ticker?

ReShape Lifesciences trades on NASDAQ under the symbol RSLS.

When does the Company fiscal year end?

The Company operates with a December 31 fiscal year end.

How can I get a copy of the Company's financial statements?

Annual Reports, Form 10-Ks, Form 10-Qs and other reports are posted to this website as soon as they are filed with the SEC.

How can I buy shares of the Company?

Contact a licensed stockbroker to purchase shares in our company.

What industry is the Company in?

The Company is a medical technology company focused on the design, development and communication of transformative technology to treat obesity and metabolic diseases.

Does the Company pay dividends?

The Company has not historically paid dividends.

Who is the Company's transfer agent?

Equiniti (formerly Wells Fargo Shareowner Services)

What is a transfer agent?

A transfer agent is a trust company, bank or similar financial institution assigned by a corporation to maintain records of investors and account balances.

What is ReShape Lifesciences' CUSIP number?

76090R101

Who are ReShape Lifesciences' independent accountants?

BDO (Costa Mesa, CA)

Which state is ReShape Lifesciences incorporated?

ReShape is incorporated in Delaware